Search

Displaying results 4041 - 4050 of 6198 in total
  1. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  2. Drug

    Dengue virus serotype 1

    go.drugbank.com/drugs/DB22664
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  3. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  4. Drug

    Tefidsogene civaparvovec

    go.drugbank.com/drugs/DB16789
    Investigational

    Developed by Sangamo Therapeutics, tefidsogene civaparvovec is being investigated in mucopolysaccharidosis type II.[A258789, L45949] … Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing.

  5. Drug

    RGX-181

    go.drugbank.com/drugs/DB17942
    Experimental

    Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072] … RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene.

  6. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    It also has an effect on viral gp160 envelope protein. [A31692] … Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid

  7. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.

  8. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  9. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx...

  10. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.